Industry Reports
The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The ultimate guide to the complex web of interactions within the U.S. prescription distribution and reimbursement system more >
The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
The most comprehensive tool for analyzing the economic and business realities of the U.S. pharmaceutical distribution industry. more >
From The Drug Channels Blog
Friday, July 17, 2026
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
Today's guest post comes from Divya Iyer, SVP, Head of Revenue, Pharma Direct at GoodRx. Divya examines why direct-to-consumer strategies shouldn't default to mail-order as the endpoint for every more >
Wednesday, July 15, 2026
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
By Adam J. Fein, Ph.D.The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted purchases under the 340B program reached an astounding more >